Healthcare Bullish Movers: Curis (NASDAQ:CRIS), Amicus Therapeutics (NASDAQ:FOLD), Akorn (NASDAQ:AKRX), Cara Therapeutics Inc (NASDAQ:CARA), Cutera (NASDAQ:CUTR)

On 5 JUNE Curis, Inc. (NASDAQ:CRIS) announced that it has re-initiated dosing in the single-agent clinical trial of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphomas. CUDC-427 is a novel, oral small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins that support survival of cancer cells. Curis, Inc. (NASDAQ:CRIS) net profit margin is -84.40% and weekly performance is 10.06%. On last trading day company shares ended up $1.86. Analysts mean target price for the company is $5.50. Curis, Inc. (NASDAQ:CRIS) distance from 50-day simple moving average (SMA50) is -2.35%.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) provided updates and detailed the statistical analysis plan for its second Phase 3 study of the oral small molecule pharmacological chaperone migalastat HCl monotherapy for Fabry patients with amenable mutations. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares advanced 10.23% in last trading session and ended the day on $3.34. FOLD return on assets is -59.30%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) quarterly performance is 61.35%.

On 20 JUNE Akorn, Inc. (NASDAQ:AKRX) announced that it has sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals (NYSE/TSX: VRX) for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. In light of this divestiture, Akorn will update its annual 2014 guidance during its fiscal second quarter earnings call in early August. Akorn, Inc. (NASDAQ:AKRX) shares moved up 4.86% in last trading session and was closed at $33.25, while trading in range of $31.71 – 33.31. Akorn, Inc. (NASDAQ:AKRX) year to date (YTD) performance is 35.05%.

On 24 JUNE Cara Therapeutics Inc (NASDAQ:CARA) announced that Dr. Robert Medve has been named Chief Medical Officer, effective immediately. Dr. Medve will oversee the clinical development of Cara’s lead compound, CR845, as well as its pipeline of other novel pain therapies. Cara Therapeutics Inc (NASDAQ:CARA) ended the last trading day at $17.02. Company weekly volatility is calculated as 6.90% and price to cash ratio as 5.74. Cara Therapeutics Inc (NASDAQ:CARA) showed a negative weekly performance of -1.05%.

Cutera, Inc. (NASDAQ:CUTR) said it was a big mover last session, as the company saw its shares rise over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend of the company. Cutera, Inc. (NASDAQ:CUTR) net profit margin is -8.30% and weekly performance is 12.32%. On last trading day company shares ended up $10.39. Analysts mean target price for the company is $12.33. Cutera, Inc. (NASDAQ:CUTR) distance from 50-day simple moving average (SMA50) is 4.70%.